Usted buscó: transplant (Maltés - Inglés)

fi provi kliniċi ta’ majeloma multipla ddijanjostikata għall-ewwel darba f’pazjenti eliġibbli għal trapjant, ġiet osservata żieda fir-rata ta’ inċidenza ta’ spm ematoloġika f’pazjenti li kienu qed jirċievu lenalidomide immedjatament wara doża għolja ta’ melphalan u trapjant awtologu ta’ Ċelluli saminali (asct - autologous stem cell transplant) meta mqabbla ma’ pazjenti li rċivew plaċebo (1.27 sa 1.56 kontra 0.46 sa 0.53 għal kull 100 sena ta’ persuna, rispettivament).
in clinical trials of newly diagnosed multiple myeloma patients eligible for transplant, an increased incidence rate of hematologic spm has been observed in patients receiving lenalidomide immediately following high- dose melphalan and autologous stem cell transplant (asct) compared with patients who received placebo (1.27 to 1.56 versus 0.46 to 0.53 per 100 person-years, respectively).